when can pharma experts testify about compliance with the FDCA? (also some survey stuff)
43(B)log
NOVEMBER 13, 2023
Nor did failure to address genericity render the survey inadmissible. And his expertise would assist the jury: he was interpreting the evidence for whether defendants were filling bulk orders in contravention of Section 503A and evaluating their suggestions for order volume according to his familiarity with industry norms and practices.
71 
Let's personalize your content